Diabetes Board decisions

The Veteran withdrew his appeals for service connection for hypertension and diabetes mellitus type II, as secondary to his service-connected bilateral knee disabilities.

The Board granted service connection for ischemic heart disease, hypertension, and diabetes mellitus under the PACT Act. The Veteran's kidney and bilateral eye disabilities were also granted as secondary to his now-service-connected diabetes mellitus.

The Board denied service connection for diabetes mellitus, type II as the evidence did not show that it was chronic in service or manifested to a compensable degree within one year of discharge; nor was there continuity of symptomatology since service.

The Board remands the issues of service connection for diabetes mellitus, hypertension, erectile dysfunction, and residuals of prostate cancer due to further development needed regarding exposure to non-herbicide agent contaminants at Fort Dix.

The Board denied service connection for right and left knee disabilities, to include osteoarthritis (OA), as well as diabetes mellitus, Type II (DM II) and peripheral artery disease (PAD).

The Board remands the veteran's claims for service connection for various disabilities, including chloracne, diabetes, peripheral neuropathy, major depressive disorder, hypertension, erectile dysfunction, and a kidney disability, to obtain further development in accordance with the Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxins Act of 2022 (PACT Act).

The Board denied service connection for an acquired psychiatric disorder, to include PTSD, and diabetes mellitus, type II, as the evidence did not support a finding of a current disability related to service.

The Board remands the matter for an addendum medical opinion to address whether the Veteran's diabetes is caused by or aggravated by his service-connected disabilities, including hypertension. Additionally, a TERA examination is required due to the Veteran's participation in toxic risk exposure activities during his ACDUTRA.

The Board granted service connection for diabetes mellitus type II, hypertension, and prostate cancer on a direct basis, effective August 10, 2022.

The Board remands the issues of entitlement to service connection for left and right foot sensorimotor peripheral neuropathy, as well as diabetes, due to a need for additional development.

The appeal was dismissed due to the Veteran's death while it was pending before the Board of Veterans' Appeals.

The Board remands the claims for service connection for various conditions, including a chronic liver disorder and diabetes mellitus, type II (DMII), due to insufficient medical evidence and required toxic exposure risk activity (TERA) opinions.

The Board denied service connection for diabetes and a prostate disorder as the evidence did not support a finding that these conditions were incurred in or aggravated by active service.

The Veteran's type II diabetes mellitus was granted an effective date of November 19, 2019, and a rating of 40 percent from that date. The claim for a higher rating was denied.

The Board denied the veteran's claim for a rating in excess of 20 percent for diabetes mellitus, type II, and remanded the issue of entitlement to a separate rating for erectile dysfunction.

The appeal for service connection for bilateral hearing loss was dismissed as the benefit sought on appeal had already been granted.

The Board granted effective dates of January 30, 2013, for the award of service connection for tinnitus, bilateral hearing loss, Type II diabetes mellitus, and coronary artery disease with stent.

The Board remands the claims for service connection for type II diabetes mellitus and sleep apnea to correct duty to assist errors.

The Board granted service connection for a heart disability, diabetes mellitus type II, and hypertension due to presumed herbicide exposure. Diabetic peripheral neuropathy of the lower extremities was also granted as secondary to diabetes.

The Veteran withdrew his appeal for service connection of type II diabetes mellitus, and the Board has no further jurisdiction over this issue.